Laparoscopic Resection in Crohn's More Cost-Effective Than Infliximab
(MedPage Today) -- More QALYs gained and 1-year health costs were $10,000 less in European study (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - February 5, 2019 Category: Gastroenterology Source Type: news

Switching Between Reference and Biosimilar Infliximab Switching Between Reference and Biosimilar Infliximab
Is switching between infliximab and its biosimilar safe and efficacious in patients with inflammatory disorders?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 17, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Biosimilar to Infliximab Switch Yields Similar IBD Outcomes (CME/CE)
(MedPage Today) -- No significant changes in clinical remission, and no new safety signals (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - January 16, 2019 Category: Rheumatology Source Type: news

Not Just Acid Reflux: The Need to Think Worst First
A previously healthy, well-appearing 42-year-old female living in a modern, high-rise apartment in downtown Los Angeles calls 9-1-1 at 5:30 am complaining of worsening of a burning, epigastric pain she had been experiencing for the last three days. She reports associated nausea and non-bloody, non-bilious vomiting, and that she couldn’t manage to get comfortable in bed until she finally decided to call for help at daybreak. During her 9-1-1 call, she reports “pain, like heartburn, that just woke me up again and I had to throw up, … and then I was sweating so much.” Using the Los Angeles Tiered Disp...
Source: JEMS Special Topics - January 13, 2019 Category: Emergency Medicine Authors: Stephen Sanko, MD, FACEP Tags: Exclusive Articles Cardiac & Resuscitation Source Type: news

Not Just Acid Reflux: The Need to Think Worst First
A previously healthy, well-appearing 42-year-old female living in a modern, high-rise apartment in downtown Los Angeles calls 9-1-1 at 5:30 am complaining of worsening of a burning, epigastric pain she had been experiencing for the last three days. She reports associated nausea and non-bloody, non-bilious vomiting, and that she couldn’t manage to get comfortable in bed until she finally decided to call for help at daybreak. During her 9-1-1 call, she reports “pain, like heartburn, that just woke me up again and I had to throw up, … and then I was sweating so much.” Using the Los Angeles Tiered Disp...
Source: JEMS Patient Care - January 13, 2019 Category: Emergency Medicine Authors: Stephen Sanko, MD, FACEP Tags: Exclusive Articles Cardiac & Resuscitation Source Type: news

Switch From Biosimilar to Originator Infliximab Safe in IBD
(MedPage Today) -- No significant changes in clinical remission, trough levels, or antidrug antibody status (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 11, 2019 Category: Gastroenterology Source Type: news

Infliximab & quot;most cost-effective option & quot; in Crohn's disease
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2019 Category: Drugs & Pharmacology Source Type: news

Infection Risk Lower With Orencia vs Anti-TNF
(MedPage Today) -- Increased risk for hospitalized infection with TNF inhibitors was driven largely by infliximab (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 26, 2018 Category: Primary Care Source Type: news

Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration
Filing for ABP 710, a Biosimilar Candidate to Infliximab, Supported by Phase 3 Study in Patients With Moderate-to-Severe Rheumatoid Arthritis THOUSAND OAKS, Calif., Dec. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to REMICADE® (infliximab). "At Amgen, we have spent nearly four decades developing, manufacturing and producing transformative medicines. We're leveraging our deep expertise and heritage in biologics to produce a portfolio of biosimilars t...
Source: Amgen News Release - December 17, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration
THOUSAND OAKS, Calif., Dec. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to REMICADE®... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 17, 2018 Category: Drugs & Pharmacology Source Type: news

Comparison of reference Infliximab and a Biosimilar (CT-P13) in Crohn's Disease (CME/CE)
(MedPage Today) -- Analysis of real-world data show that CT-P13 is equivalent to infliximab in infliximab-naive patients with CD (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - December 12, 2018 Category: Gastroenterology Source Type: news

Biosimilar CT-P13 Matches Infliximab for Crohn's Disease Biosimilar CT-P13 Matches Infliximab for Crohn's Disease
Crohn's disease was effectively and safely treated either with infliximab or with the biosimilar CT-P13, according to an observational cohort study of more than 5000 patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 12, 2018 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Reference Infliximab, Biosimilar Equivalent for Crohn's Disease
TUESDAY, Dec. 11, 2018 -- CT-P13, which is a biosimilar of the reference product (RP) infliximab, has equivalent effectiveness for infliximab-naive patients with Crohn's disease (CD), according to a study published online Dec. 11 in the Annals of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 11, 2018 Category: Pharmaceuticals Source Type: news

Biosimilar CT-P13 Matches Infliximab in Crohn ’s Disease
(MedPage Today) -- With comparable safety and efficacy, drug choice may come down to cost (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - December 11, 2018 Category: Gastroenterology Source Type: news

Novartis launches third-to-market Remicade copy in Germany
Novartis launched a copy of Johnson& Johnson's (J&J) inflammation-fighting Remicade in Germany on Thursday as the Swiss drugmaker aims to catch rival biosimilars that are already available in Europe's largest healthcare market. (Source: Reuters: Health)
Source: Reuters: Health - November 15, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Johnson & Johnson edges past profit estimates, lifts outlook
Johnson& Johnson reported slightly better-than-expected quarterly profit on Tuesday and pushed its full-year forecast higher, as demand for its cancer drugs Zytiga and Imbruvica helped offset falling sales of arthritis treatment Remicade. (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Johnson & Johnson profit beats, lifts forecast on cancer drug demand
Johnson& Johnson on Tuesday reported quarterly profit above estimates and raised its full-year forecast, as demand for its cancer drugs Zytiga and Imbruvica helped offset decline in sales of blockbuster drug, Remicade. (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Infliximab Biosimilar vs Infliximab Reference Product for RA Infliximab Biosimilar vs Infliximab Reference Product for RA
How does this infliximab biosimilar and the reference product compare in terms of efficacy, safety, pharmacokinetics, and immunogenicity?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Out-of-Pocket Costs Similar for Infliximab, Infliximab-Dyyb
WEDNESDAY, Sept. 5, 2018 -- Under Medicare Part D, out-of-pocket costs are similar for infliximab and its biosimilar infliximab-dyyb, according to a research letter published in the Sept. 4 issue of the Journal of the American Medical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 5, 2018 Category: Pharmaceuticals Source Type: news

Is Infliximab Associated with Infection Risk in Psoriasis?
(MedPage Today) -- New study suggests it is (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - August 12, 2018 Category: Rheumatology Source Type: news

Study Supports Safety of Infliximab in Pregnancy Study Supports Safety of Infliximab in Pregnancy
New registry data should help reassure women with Crohn's disease (CD) who need to continue infliximab during pregnancy that it won't harm their baby.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 30, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

High Infliximab Levels Offer Safe Inflammation Control in IBD (CME/CE)
(MedPage Today) -- No increase in infections with trough levels>7 ug/mL (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - July 17, 2018 Category: Gastroenterology Source Type: news

J & J beats quarterly expectations on drug sales surge, shares jump
Johnson& Johnson on Tuesday reported better-than-expected second quarter profit as sales of pharmaceuticals surged 20 percent despite a sharp decline in blockbuster arthritis drug Remicade, and its shares rose more than 4 percent. (Source: Reuters: Health)
Source: Reuters: Health - July 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Johnson & Johnson profit beat fueled by strength in pharma business
Johnson& Johnson topped analysts' estimates for quarterly profit and revenue on Tuesday, as strong demand for cancer drugs Zytiga and Darzalex more than made up for declining sales of blockbuster treatment Remicade. (Source: Reuters: Health)
Source: Reuters: Health - July 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Inflectra (Infliximab-Dyyb Intravenous Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 2, 2018 Category: Drugs & Pharmacology Source Type: news

Renflexis (Infliximab-abda Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 2, 2018 Category: Drugs & Pharmacology Source Type: news

No Surgical Gains from Accelerated Infliximab in Acute UC
(MedPage Today) -- Colectomy rates similar to those with standard induction therapy (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 29, 2018 Category: Gastroenterology Source Type: news

Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab
Study Evaluated Efficacy and Safety of ABP 710 Compared With Infliximab in Patients With Moderate-to-Severe Rheumatoid Arthritis Amgen to Seek Regulatory Approvals THOUSAND OAKS, Calif., June 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 710 compared with REMICADE® (infliximab) in patients with moderate-to-severe rheumatoid arthritis. The results confirm non-inferiority compared to infliximab but could not rule out superiority based on its primary efficacy endpoint, which compared the response differen...
Source: Amgen News Release - June 27, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Novartis touts effectiveness, safety of autoimmune drug copies
ZURICH (Reuters) - Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson& Johnson's Remicade and Amgen Inc's Enbrel, citing a study it hopes will help convince doctors that switching from the original medicines is a viable alternative for treating autoimmune diseases. (Source: Reuters: Health)
Source: Reuters: Health - June 15, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis receives EU approval for biosimilar Zessly
ZURICH (Reuters) - Novartis said its Sandoz division received approval from the European Commission for its biosimilar Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases. (Source: Reuters: Health)
Source: Reuters: Health - May 24, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

IBD Patients in Remission Can Safely Switch to Infliximab Biosimilar IBD Patients in Remission Can Safely Switch to Infliximab Biosimilar
Switching to CT-P13, an infliximab biosimilar, is safe and well tolerated in patients with IBD whose disease is in remission, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 13, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

EMA Committee Backs Remicade Biosimilar Zessly EMA Committee Backs Remicade Biosimilar Zessly
The committee favors marketing the infliximab biosimilar product Zessly for treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 23, 2018 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news

Switching From Infliximab to Biosimilar in Patients With IBD Switching From Infliximab to Biosimilar in Patients With IBD
Two infliximab biosimilars are currently available for the treatment of inflammatory bowel disease, at a much lower cost than infliximab innovator. Can patients be safely switched?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 20, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Symptoms Sufficient to Prompt Infliximab-dose Increases in Crohn's Disease Symptoms Sufficient to Prompt Infliximab-dose Increases in Crohn's Disease
Symptoms alone are as useful as a combination of symptoms, biomarkers and serum drug concentrations for determining the need for an increased dose of infliximab in patients with Crohn's disease (CD), according to results from a randomized trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 29, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

U.S. Appeals Court Invalidates J & J Patent on Remicade U.S. Appeals Court Invalidates J & J Patent on Remicade
A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson& Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J ’ s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 24, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

U.S. appeals court upholds ruling invalidating J & J patent on Remicade
(Reuters) - A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson& Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J ’s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug. (Source: Reuters: Health)
Source: Reuters: Health - January 23, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Biosimilars, Biologics, New Legal Challenges for RA Treatments Biosimilars, Biologics, New Legal Challenges for RA Treatments
Early last winter, Pfizer launched its new rheumatoid arthritis treatment, Inflectra, pricing it 15 percent below the $4,000-a-dose wholesale price of Remicade, the drug for which it is a close copy.Kaiser Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 29, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

FDA approves new Pfizer biosimilar
Pfizer Inc. (NYSE:PFE) announced that the United States (U.S.) Food and Drug Administration (FDA) has approved IXIFI™ (PF-06438179, infliximab-qbtx), a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade® (infliximab) for all eligible indications of the reference product. (Source: World Pharma News)
Source: World Pharma News - December 15, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

FDA Clears Another Remicade Biosimilar (Ixifi) FDA Clears Another Remicade Biosimilar (Ixifi)
The FDA has approved Pfizer's infliximab-qbtx (Ixifi) for all eligible indications for the US-licensed reference product.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2017 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news

Pfizer's second biosimilar of J & J's Remicade wins U.S. FDA approval
(Reuters) - The U.S. Food and Drug Administration approved Pfizer Inc's second biosimilar to Johnson& Johnson's blockbuster rheumatoid arthritis drug, Remicade, the company said on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - December 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Ixifi (infliximab-qbtx), a Biosimilar to Remicade
December 13, 2017 -- Pfizer Inc. (NYSE:PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Ixifi (PF-06438179, infliximab-qbtx), a chimeric human-murine monoclonal antibody (mAb) against tumor... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 13, 2017 Category: Drugs & Pharmacology Source Type: news

Janssen drops U.S. lawsuit against Samsung Bioepis' Remicade copy
SEOUL (Reuters) - A unit of healthcare conglomerate Johnson& Johnson has dropped a lawsuit it filed to block a copy of its rheumatoid arthritis drug Remicade produced by South Korea's Samsung Bioepis Co Ltd from being sold in the United States. (Source: Reuters: Health)
Source: Reuters: Health - November 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

RA Efficacy, Safety Similar After Infliximab-to-SB2 Switch RA Efficacy, Safety Similar After Infliximab-to-SB2 Switch
Patients with RA who switched from infliximab to the biosimilar SB2 had ACR20 responses, adverse events, and immunogenicity profiles at 78 weeks similar to those in patients who continued infliximab.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 13, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Long-term Studies Back Biologic-to-Biosimilar Switch Long-term Studies Back Biologic-to-Biosimilar Switch
Researchers in Europe compared clinical response, remission, and immunogenicity to determine whether switching between innovator infliximab and the CTP-13 biosimilar has any effect on outcomes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 1, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

IBD patients may stay healthier when doctors monitor medications before they lose efficacy
(Beth Israel Deaconess Medical Center) Proactive monitoring of blood levels of the therapeutic drug infliximab was associated with improved outcomes including lower risk of surgery and hospitalization. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 3, 2017 Category: International Medicine & Public Health Source Type: news

Pfizer Files Suit Over Remicade Contracts Pfizer Files Suit Over Remicade Contracts
Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 21, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Surgery an Alternative to Infliximab for Some People With Crohn ’ s Disease Surgery an Alternative to Infliximab for Some People With Crohn ’ s Disease
Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 21, 2017 Category: Surgery Tags: General Surgery News Source Type: news

Pfizer files lawsuit against J & J ’s exclusionary contracts for Remicade
Pfizer has filed a lawsuit against Johnson& Johnson (J&J) in the US District Court for the Eastern District of Pennsylvania to ensure patients and providers have access to major, lower-cost biosimilar therapies. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 20, 2017 Category: Pharmaceuticals Source Type: news

Pfizer sues J&J, claims ‘anticompetitive practices’ over Remicade biosimilar
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - September 20, 2017 Category: Pharmaceuticals Source Type: news

Merck, Samsung Bioepis launch discounted U.S. Remicade alternative
NEW YORK/SEOUL (Reuters) - Merck& Co and South Korea's Samsung Bioepis Co Ltd said on Monday they have begun selling a less expensive alternative version of Johnson& Johnson's rheumatoid arthritis drug Remicade in the United States, a move that should accelerate price declines for the big-selling medicine. (Source: Reuters: Health)
Source: Reuters: Health - July 24, 2017 Category: Consumer Health News Tags: healthNews Source Type: news